Literature DB >> 9507121

Cortical spreading depression-associated hyperemia in rats: involvement of serotonin.

L Gold1, T Back, G Arnold, J Dreier, K M Einhäupl, U Reuter, U Dirnagl.   

Abstract

We investigated whether the vasoactive neurotransmitter serotonin (5-HT) is involved in cortical spreading depression (CSD)-associated hyperemia in the rat. We focused on the 5-HT2 receptor, which is engaged in 5-HT induced small arteriolar relaxation in cats, as well as on the 5-HT1D/1B receptor, the binding site of the potent antimigraine drug sumatriptan. In male barbiturate anaesthetized Wistar rats (n=25) CSDs were elicited by brain topical application of 1 M KCl, and the DC-potential and regional cerebral blood flow (rCBF, by Laser Doppler flowmetry) were measured over the same hemisphere through dura and thinned bone, respectively. Intravenous application of 8 mg/kg of the 5-HT2A/2C receptor antagonist ritanserin (group I; n=8) significantly reduced the hyperperfusion amplitude during CSD by approximately 44% (p<0.05, from 342+/-124 to 194+/-97%, baseline before CSD=100%), and prolonged its duration by approx. 30%. Vehicle alone (group II; n=4) did not affect CSD hyperperfusion. The highly selective 5-HT1D/1B receptor agonist 311C90 was given in two doses: 100 micrograms/kg i.v. (n=5) had no effect on CSD hyperperfusion, while 800 micrograms/kg (n=5) increased hyperperfusion significantly (p<0.05, from 224+/-86 to 310+/-148%). We conclude that serotonin is, probably via 5-HT2 receptors, involved in the modulation of the regional cerebral blood flow increase during CSD. Novel highly selective receptor antagonists may help to discriminate the differential contribution of various 5-HT receptor subspecies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9507121     DOI: 10.1016/s0006-8993(97)01341-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  An implantable multimodal sensor for oxygen, neurotransmitters, and electrophysiology during spreading depolarization in the deep brain.

Authors:  Caddy N Hobbs; Justin A Johnson; Matthew D Verber; R Mark Wightman
Journal:  Analyst       Date:  2017-08-07       Impact factor: 4.616

Review 2.  Spreading Depression, Spreading Depolarizations, and the Cerebral Vasculature.

Authors:  Cenk Ayata; Martin Lauritzen
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

Review 3.  [Cortical spreading depression (CSD): a neurophysiological correlate of migraine aura].

Authors:  F Richter; A Lehmenkühler
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

Review 4.  Mechanisms involved in the cerebrovascular dilator effects of cortical spreading depression.

Authors:  David W Busija; Ferenc Bari; Ferenc Domoki; Takashi Horiguchi; Katsuyoshi Shimizu
Journal:  Prog Neurobiol       Date:  2008-09-12       Impact factor: 11.685

5.  Cortical spreading depression increases the phosphorylation of AMP-activated protein kinase in the cerebral cortex.

Authors:  Emanuela Viggiano; Davide Viggiano; Alessandro Viggiano; Bruno De Luca; Marcellino Monda
Journal:  Neurochem Res       Date:  2014-10-12       Impact factor: 3.996

6.  Neuroprotection and acidosis induced by cortical spreading depression.

Authors:  Kenneth K Kwong; Suk-Tak Chan
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-12       Impact factor: 2.570

7.  Systemic inflammation alters central 5-HT function as determined by pharmacological MRI.

Authors:  Yvonne Couch; Chris J Martin; Clare Howarth; Josie Raley; Alexandre A Khrapitchev; Michael Stratford; Trevor Sharp; Nicola R Sibson; Daniel C Anthony
Journal:  Neuroimage       Date:  2013-03-05       Impact factor: 6.556

8.  Cortical spreading depression produces a neuroprotective effect activating mitochondrial uncoupling protein-5.

Authors:  Emanuela Viggiano; Vincenzo Monda; Antonietta Messina; Fiorenzo Moscatelli; Anna Valenzano; Domenico Tafuri; Giuseppe Cibelli; Bruno De Luca; Giovanni Messina; Marcellino Monda
Journal:  Neuropsychiatr Dis Treat       Date:  2016-07-11       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.